4.7 Article

Clioquinol Decreases Levels of Phosphorylated, Truncated, and Oligomerized Tau Protein

Journal

Publisher

MDPI
DOI: 10.3390/ijms222112063

Keywords

Alzheimer's disease; clioquinol; tau protein; tau oligomer; JNK; PP2A; p38MAPK; metal protein attenuating compounds; autophagy

Funding

  1. health and family planning commission of Zhejiang province [2015KYB016]
  2. JSPS KAKENHI [19K07909]
  3. Ministry of Health, Labor and Welfare, Japan, and a research
  4. University of Fukui [LSI20306]
  5. Grants-in-Aid for Scientific Research [19K07909] Funding Source: KAKEN

Ask authors/readers for more resources

The neuropathological features of Alzheimer's disease are senile plaques and neurofibrillary tangles, which are composed of amyloid beta protein and phosphorylated tau protein respectively. Metal regulation, especially with compounds like clioquinol, may be a potential direction for AD treatment. Clioquinol has been shown to decrease metal accumulation, tau phosphorylation, and activate pathways involved in tau protein degradation, potentially offering new insights into AD therapeutics.
The neuropathological hallmarks of Alzheimer's disease (AD) are senile plaques (SPs), which are composed of amyloid beta protein (A beta), and neurofibrillary tangles (NFTs), which consist of highly phosphorylated tau protein. As bio-metal imbalance may be involved in the formation of NFT and SPs, metal regulation may be a direction for AD treatment. Clioquinol (CQ) is a metal-protein attenuating compound with mild chelating effects for Zn2+ and Cu2+, and CQ can not only detach metals from SPs, but also decrease amyloid aggregation in the brain. Previous studies suggested that Cu2+ induces the hyperphosphorylation of tau. However, the effects of CQ on tau were not fully explored. To examine the effects of CQ on tau metabolism, we used a human neuroblastoma cell line, M1C cells, which express wild-type tau protein (4R0N) via tetracycline-off (TetOff) induction. In a morphological study and ATP assay, up to 10 mu M CQ had no effect on cell viability; however, 100 mu M CQ had cytotoxic effects. CQ decreased accumulation of Cu+ in the M1C cells (39.4% of the control), and both total and phosphorylated tau protein. It also decreased the activity of c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK) (37.3% and 60.7% levels of the control, respectively), which are tau kinases. Of note, activation of protein phosphatase 2A (PP2A), which is a tau phosphatase, was also observed after CQ treatment. Fractionation experiments demonstrated a reduction of oligomeric tau in the tris insoluble, sarkosyl soluble fraction by CQ treatment. CQ also decreased caspase-cleaved tau, which accelerated the aggregation of tau protein. CQ activated autophagy and proteasome pathways, which are considered important for the degradation of tau protein. Although further studies are needed to elucidate the mechanisms responsible for the effects of CQ on tau, CQ may shed light on possible AD therapeutics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available